Nam Keun Kim, Ph.D., Young Joo Jeon, M.S., Young Ran Kim, M.D., Bo Eun Lee, M.S., Sun Hee Cha, M.D., Ph.D., Doyeun Oh, M.D., Ph.D., Woo Sik Lee, M.D., Ph.D., Myoung-Jin Moon, M.D., Ph.D.
Volume 101, Issue 3, Pages 825-832.e1, March 2014
To investigate the association between potentially functional plasminogen activator inhibitor-1 (PAI-1) genetic polymorphisms and primary ovarian insufficiency (POI).
Urban university-based hospital.
A cohort of 137 POI patients and 227 controls.
Main Outcome Measure(s):
Genotyping of five PAI-1 polymorphisms (−844G>A [rs2227631], −675 4G/5G [rs1799889], 43G>A (Ala>Thr) [rs6092], 9785G>A [rs2227694], and 11053T>G [rs7242]) was assessed by polymerase chain reaction–restriction fragment length polymorphism assay.
PAI-1 polymorphisms 9785GA+AA, −844A/9785A, 4G/9785A, and 9785A/11053G were associated with POI occurrence. Moreover, −844GA+AA and 11053TG+GG were associated with lower serum E2 levels in controls.
We have identified an association between five PAI-1 polymorphisms and POI occurrence. However, the mechanism underlying the function of these polymorphisms in POI remains to be determined. Further studies are needed to improve understanding of the roles of PAI-1 polymorphisms and genes in related pathways, using a larger and more heterogeneous cohort.
Read the full text at: http://www.fertstert.org/article/S0015-0282(13)03268-8/fulltext